Last ¥1,721 JPY
Change Today +4.00 / 0.23%
Volume 313.9K
4541 On Other Exchanges
Symbol
Exchange
OTC US
Tokyo
As of 2:00 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

nichi-iko pharmaceutical co (4541) Snapshot

Open
¥1,717
Previous Close
¥1,717
Day High
¥1,721
Day Low
¥1,701
52 Week High
10/30/13 - ¥1,942
52 Week Low
05/21/14 - ¥1,403
Market Cap
104.4B
Average Volume 10 Days
302.4K
EPS TTM
¥112.61
Shares Outstanding
60.7M
EX-Date
09/26/14
P/E TM
15.3x
Dividend
¥24.60
Dividend Yield
1.44%
Current Stock Chart for NICHI-IKO PHARMACEUTICAL CO (4541)

Related News

No related news articles were found.

nichi-iko pharmaceutical co (4541) Related Businessweek News

No Related Businessweek News Found

nichi-iko pharmaceutical co (4541) Details

Nichi-Iko Pharmaceutical Co., Ltd. is engaged in the manufacture, sale, distribution, export, import, and related activities for various pharmaceuticals. The company primarily focuses on the production of generic drugs. It also offers treatments for circulatory, digestive, respiratory, and central and peripheral nervous system disorders. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was founded in 1965 and is headquartered in Toyama, Japan.

926 Employees
Last Reported Date: 06/20/14
Founded in 1965

nichi-iko pharmaceutical co (4541) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nichi-iko pharmaceutical co (4541) Key Developments

Nichi-Iko Pharmaceutical to Launch Five APIs in Thailand in October

Nichi-Iko Pharmaceutical has announced plans to launch five active pharmaceutical ingredients (APIs) in Thailand in October, including gastric ulcer treatments and topical steroids. Significance:Nichi-Iko has previously suggested it is planning to launch nine unspecified generic drugs in Thailand during 2014, with a focus on treatments for cardiovascular diseases, diabetes, and alimentary canal diseases, therefore more drug launches may still be in the pipeline. The launch is the latest step in Nichi-Iko's drive to target regional growth in Southeast Asia, which is expected to receive a boost from the opening of the ASEAN Economic Community (AEC) in 2015.

Nichi-Iko Pharmaceutical Co., Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2014; Plans to Pay Interim Divided; Provides Earnings Guidance for Fiscal 2015

Nichi-Iko Pharmaceutical Co., Ltd. reported unaudited consolidated earnings results for the first quarter ended June 30, 2014. For the period, the company reported net sales of ¥30,400 million compared with ¥24,587 million for the same period last year. Operating income of ¥2,593 million compared with ¥2,213 million for the same period last year. Ordinary income of ¥2,549 million compared with ¥2,263 million for the same period last year. Net income of ¥1,913 million or ¥31.99 diluted per share compared with ¥1,233 million or ¥30.93 diluted per share for the same period last year. The company plans to pay interim dividend of ¥12.30 and final dividend of ¥14.30 per share for the fiscal year ending March 31, 2015. For the second quarter of fiscal 2015, the company expects net sales of ¥59,200 million, Operating income of ¥4,000, Ordinary income of ¥3,800 million and net income of ¥2,500 million or ¥41.81. For the full year, the company expects net sales of ¥123,000 million, Operating income of ¥9,300, Ordinary income of ¥9,000 million and net income of ¥5,900 million or ¥98.68.

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q1, 2015 Results on Aug 11, 2014

Nichi-Iko Pharmaceutical Co., Ltd. announced that they will report Q1, 2015 results at 3:00 PM, Tokyo Standard Time on Aug 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4541:JP ¥1,721.00 JPY +4.00

4541 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4541.
View Industry Companies
 

Industry Analysis

4541

Industry Average

Valuation 4541 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NICHI-IKO PHARMACEUTICAL CO, please visit www.nichiiko.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.